Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Processa Pharmaceuticals (PCSA)
NASDAQ:PCSA
RESEARCH TOOLSreports
Processa Pharmaceuticals (PCSA) Stock Price & Analysis
102 Followers
PCSA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.40 - $18.02
Previous Close$2.22
Volume48.08K
Average Volume (3M)1.51M
Market Cap
$6.34M
Enterprise Value-$2.16M
Total Cash (Recent Filing)$8.70M
Total Debt (Recent Filing)$191.22K
Price to Earnings (P/E)-0.3
Beta1.33
Next Earnings
Mar 28, 2024EPS Estimate
-$1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding2,858,007
10 Day Avg. Volume154,640
30 Day Avg. Volume1,506,556
Standard Deviation0.30
R-Squared0.00891
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.09
Forecast
1Y Price Target
$8.00Price Target Upside260.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Processa Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsProcessa announced positive safety and preliminary efficacy data from its Phase 1b study of PCS6422 Next Generation Capecitabine (NGC).
Product DevelopmentOptimizing existing chemotherapeutic agents to enhance safety, tolerability and effectiveness for a wide array of cancer sufferers.
Stock RatingBuy rating and 12-month price target of $8 per share.
Bears Say
Company StrategyLow market capitalization reflects challenges faced since the company changed strategy to focus exclusively on the oncology drug portfolio.
Drug Safety ConcernsThe highest dose of the company's leading drug was associated with a high incidence rate of myelosuppression, posing serious safety concerns.
Financial ConcernsThe gating factor for the company's clinical advancement is the looming financing overhang.
---
Ownership Overview
67.80% Insiders
12.35% Mutual Funds
0.85% Other Institutional Investors
19.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PCSA FAQ
What was Processa Pharmaceuticals’s price range in the past 12 months?
Processa Pharmaceuticals lowest stock price was $1.40 and its highest was $18.02 in the past 12 months.
What is Processa Pharmaceuticals’s market cap?
Currently, no data Available
When is Processa Pharmaceuticals’s upcoming earnings report date?
Processa Pharmaceuticals’s upcoming earnings report date is Mar 28, 2024 which is 47 days ago.
How were Processa Pharmaceuticals’s earnings last quarter?
Processa Pharmaceuticals released its earnings results on Nov 08, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.02.
Is Processa Pharmaceuticals overvalued?
According to Wall Street analysts Processa Pharmaceuticals’s price is currently Undervalued.
Does Processa Pharmaceuticals pay dividends?
Processa Pharmaceuticals does not currently pay dividends.
What is Processa Pharmaceuticals’s EPS estimate?
Processa Pharmaceuticals’s EPS estimate is -$1.6.
How many shares outstanding does Processa Pharmaceuticals have?
Processa Pharmaceuticals has 2,858,007 shares outstanding.
What happened to Processa Pharmaceuticals’s price movement after its last earnings report?
Processa Pharmaceuticals reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went up 3.965%.
Which hedge fund is a major shareholder of Processa Pharmaceuticals?
Currently, no hedge funds are holding shares in PCSA
---
Processa Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (260.36% Upside)
$8.00 (260.36% Upside)
Blogger Sentiment
Bullish
PCSA Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.56%
12-Months-Change
Fundamentals
Return on Equity
-103.29%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. It focuses on its product, PCS-499, which is an oral tablet that is a deuterated analog of an active metabolite of an already approved drug. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.
---
PCSA Earnings Call
Q4 2023
0:00 / 0:00
---
PCSA Stock 12 Month Forecast
Average Price Target
$8.00
▲(260.36% Upside)
Technical Analysis
Galectin Therapeutics
―
Aurinia Pharmaceuticals
―
Corbus Pharmaceuticals
―
Citius Pharmaceuticals
―
Best Analysts Covering PCSA
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-4.30%
reiterated a buy rating 2 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -4.30% per trade.
---